Saint-Herblain (France), June 3, 2022Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies Healthcare Conference which will take place from June 8 to 10, 2022 in New York.

Valneva’s Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will notably discuss the Company’s late-stage vaccine candidates against Lyme disease (VLA15), chikungunya (VLA1553) and COVID-19 (VLA2001).

Valneva was recently granted Conditional Marketing Authorization in the United Kingdom for its inactivated COVID-19 vaccine candidate VLA2001[1] and filed a Marketing Authorization Application with the European Medicines in May 2022[2]. The Company also recently commenced the pre-submission process with the US Food and Drug Administration for its single-shot chikungunya vaccine candidate VLA1553 after reporting final positive pivotal Phase 3 results[3] and lot-to-lot data[4]. Additionally, in April 2022, Valneva and its partner Pfizer reported first positive pediatric results for their Lyme disease vaccine candidate VLA15[5]. These positive data build on the strong immunogenicity profile reported for adult participants (18-65 years old) in February 2022, and the two companies expect to proceed with a Phase 3 clinical trial in participants age 5-65, which is planned to start in the third quarter of 2022.

The fireside chat at the Jefferies conference will take place on June 9, 2022 at 11:30am EDT (17:30 CEST) and will be accessible live via the following link, https://wsw.com/webcast/jeff240/valn/1848225. Eine Aufzeichnung des Webcasts wird im Anschluss an die Live-Veranstaltungen im Bereich "Investoren" auf der Valneva-Website verfügbar sein: www.valneva.com.

Wenn Sie einen Gesprächstermin auf der Veranstaltung wünschen, wenden Sie sich bitte an Ihren Vertreter bei Jefferies.

Über Valneva SE

Valneva ist ein Impfstoffunternehmen, das sich auf die Entwicklung und Vermarktung von prophylaktischen Impfstoffen gegen Infektionskrankheiten mit hohem ungedeckten medizinischen Bedarf spezialisiert hat. Das Unternehmen verfolgt bei der Impfstoffentwicklung einen hochspezialisierten und zielgerichteten Ansatz an und wendet sein tiefes Verständnis der Impfstoffwissenschaft an, um prophylaktische Impfstoffe gegen diese Krankheiten zu entwickeln. Durch Einsatz seines Fachwissens und seiner Fähigkeiten konnte das Unternehmen zwei Impfstoffe erfolgreich vermarkten und mehrere Impfstoffkandidaten schnell in und durch die klinische Entwicklung bringen, darunter Kandidaten gegen Borreliose, das Chikungunya-Virus und COVID-19.

Kontakte für Investoren und Medien

Laetitia Bachelot-Fontaine

VP, Global Communications and European Investor Relations

M +33 (0)6 4516 7099

communications@valneva.com

 

 

 

 

Teresa Pinzolits

Corporate Communications Specialist

T +43-1-206 20-1116

teresa.pinzolits@valneva.com

 

 

 

 

 

Zukunftsgerichtete Aussagen

This press release contains certain forward-looking statements relating to the business of Valneva, including but not limited to the initiation of clinical trials and product approvals. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of future results. In some cases, you can identify forward-looking statements by words such as “könnte,” “sollte,” “könnte” “erwartet,” “antizipiert,” “glaubt,” “beabsichtigt,” “schätzt,” “strebt an,” “zielt darauf ab,” or similar words. These forward-looking statements are based on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patent or other proprietary intellectual property protection, the cancellation of existing contracts, including but not limited to the VLA2001 supply agreement with the UK government, and the impact of the COVID-19 pandemic, the occurrence of any of which could substantially harm Valneva’s business, financial condition, prospects and results of operations. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

[1] Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine – Valneva

[2] EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 Vaccine Candidate – Valneva

[3] Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate – Valneva

[4] Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate – Valneva

[5] Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate – Valneva